Systematic review of the performance and clinical utility of point of care HIV-1 RNA testing for diagnosis and care

Clara A Agutu, Caroline J Ngetsa, Matt A Price, Tobias F Rinke de Wit, Gloria Omosa-Manyonyi, Eduard J Sanders, Susan M Graham, Clara A Agutu, Caroline J Ngetsa, Matt A Price, Tobias F Rinke de Wit, Gloria Omosa-Manyonyi, Eduard J Sanders, Susan M Graham

Abstract

Background: Point of-care (POC) HIV-1 RNA tests which are accurate and easy to use with limited infrastructure are needed in resource-limited settings (RLS). We systematically reviewed evidence of POC test performance compared to laboratory-based HIV-1 RNA assays and the potential utility of these tests for diagnosis and care in RLS.

Methods: Studies published up to July 2018 were identified by a search of PUBMED, EMBASE, Web of Science, CINAHL and Cochrane Central Register of Controlled Trials. Studies evaluating the use of POC HIV-1 RNA testing for early infant diagnosis (EID), acute HIV infection (AHI) diagnosis, or viral load monitoring (VL), compared to centralized testing, were included. Separate search strategies were used for each testing objective.

Results: 197 abstracts were screened and 34 full-text articles were assessed, of which 32 met inclusion criteria. Thirty studies evaluated performance and diagnostic accuracy of POC tests compared to standard reference tests. Two of the thirty and two additional studies with no comparative testing reported on clinical utility of POC results. Five different POC tests (Cepheid GeneXpert HIV-1 Quantitative and Qualitative assays, Alere q HIV-1/2 Detect, SAMBA, Liat HIV Quant and Aptima HIV-1 Quant) were used in 21 studies of VL, 11 of EID and 2 of AHI. POC tests were easy to use, had rapid turnaround times, and comparable accuracy and precision to reference technologies. Sensitivity and specificity were high for EID and AHI but lower for VL. For VL, lower sensitivity was reported for whole blood and dried blood spots compared to plasma samples. Reported error rates for Cepheid GeneXpert Qual (2.0%-5.0%), GeneXpert Quant (2.5%-17.0%) and Alere q HIV-1/2 Detect (3.1%-11.0%) were higher than in WHO prequalification reports. Most errors resolved with retesting; however, inadequate sample volumes often precluded repeat testing. Only two studies used POC results for clinical management, one for EID and another for VL. POC EID resulted in shorter time-to-result, rapid ART initiation, and better retention in care compared to centralised testing.

Conclusions: Performance of POC HIV-1 RNA tests is comparable to reference assays, and have potential to improve patient outcomes. Additional studies on implementation in limited-resources settings are needed.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Flow diagram of study selection.
Fig 1. Flow diagram of study selection.
Fig 2. Sensitivity of Cepheid GeneXpert HIV-1…
Fig 2. Sensitivity of Cepheid GeneXpert HIV-1 RNA Qual for early infant diagnosis.
Fig 3. Alere Q HIV½ Detect (Qual)…
Fig 3. Alere Q HIV½ Detect (Qual) for Early Infant Diagnosis.

References

    1. Niemz A, Ferguson TM, Boyle DS. Point-of-care nucleic acid testing for infectious diseases. Trends in Biotechnology. 2011;29(5):240–50. 10.1016/j.tibtech.2011.01.007
    1. Usdin M, Guillerm M, Calmy A. Patient needs and point-of-care requirements for HIV load testing in resource-limited settings. Journal of infectious diseases. 2010;201(Supplement 1):S73–S7.
    1. UNITAID WHO. HIV/AIDS Diagnostics Technology Landscape 5th edition October 2015 [cited 2017 06 Feb 2017 ]. Available from: .
    1. Shafiee H, Wang S, Inci F, Toy M, Henrich TJ, Kuritzkes DR, et al. Emerging technologies for point-of-care management of HIV infection. Annual review of medicine. 2015;66:387–405. 10.1146/annurev-med-092112-143017
    1. Rosenberg NE, Kamanga G, Phiri S, Nsona D, Pettifor A, Rutstein SE, et al. Detection of Acute HIV Infection: A Field Evaluation of the Determine® HIV-1/2 Ag/Ab Combo Test. The Journal of Infectious Diseases. 2012;205(4):528–34. 10.1093/infdis/jir789
    1. Lewis JM, Macpherson P, Adams ER, Ochodo E, Sands A, Taegtmeyer M. Field accuracy of 4th generation rapid diagnostic tests for acute HIV-1: a systematic review. AIDS (London, England). 2015;29(18):2465–71. 10.1097/QAD.0000000000000855 PMC4645957.
    1. WHO. WHO list of prequalified in vitro diagnostic products 2019 [updated 04 April 2019; cited 2019 06 May]. Available from: .
    1. WHO. WHO Prequalification of In Vitro Diagnostics Public Report: m-PIMA HIV-1/2 VL 2019 [updated April 2019; cited 2019 06 May]. Available from: .
    1. WHO. Virological Technologies: progress of the active applications in the prequalification of IVDs assessment pipeline 2019 [updated 23 April 2019; cited 2019 06 May]. Available from: .
    1. Scott L, Gous N, Carmona S, Stevens W. Laboratory evaluation of the Liat HIV Quant (IQuum) whole-blood and plasma HIV-1 viral load assays for point-of-care testing in South Africa. Journal of clinical microbiology. 2015;53(5):1616–21. 10.1128/JCM.03325-14
    1. Nash M, Huddart S, Badar S, Baliga S, Saravu K, Pai M. Performance of the Xpert® HIV-1 Viral Load assay: A systematic review and meta-analysis. Journal of clinical microbiology. 2018:JCM. 01673–17.
    1. Ritchie AV, Goel N, Sembongi H, Lehga J, Farleigh LE, Edemaga D, et al. Performance evaluation of the point-of-care SAMBA I and II HIV-1 Qual whole blood tests. Journal of Virological Methods. 2016;237:143–9. 10.1016/j.jviromet.2016.08.017
    1. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ: British Medical Journal. 2003;326(7379):41–4. PMC1124931. 10.1136/bmj.326.7379.41
    1. Ndlovu Z, Fajardo E, Mbofana E, Maparo T, Garone D, Metcalf C, et al. Multidisease testing for HIV and TB using the GeneXpert platform: A feasibility study in rural Zimbabwe. PloS one. 2018;13(3):e0193577 10.1371/journal.pone.0193577
    1. Technau K-G, Kuhn L, Coovadia A, Murnane PM, Sherman G. Xpert HIV-1 point-of-care test for neonatal diagnosis of HIV in the birth testing programme of a maternity hospital: a field evaluation study. The Lancet HIV. 2017;4(10):e442–e8. 10.1016/S2352-3018(17)30097-8
    1. Jani IV, Meggi B, Loquiha O, Tobaiwa O, Mudenyanga C, Zitha A, et al. Effect of point-of-care early infant diagnosis on antiretroviral therapy initiation and retention of patients. AIDS. 2018;32(11):1453–63. 10.1097/QAD.0000000000001846 00002030-201807170-00008.
    1. Meggi B, Vojnov L, Mabunda N, Vubil A, Zitha A, Tobaiwa O, et al. Performance of point-of-care birth HIV testing in primary health care clinics: An observational cohort study. PLOS ONE. 2018;13(6):e0198344 10.1371/journal.pone.0198344
    1. Ceffa S, Luhanga R, Andreotti M, Brambilla D, Erba F, Jere H, et al. Comparison of the Cepheid GeneXpert and Abbott M2000 HIV-1 real time molecular assays for monitoring HIV-1 viral load and detecting HIV-1 infection. Journal of virological methods. 2016;229:35–9. 10.1016/j.jviromet.2015.12.007
    1. Dunning L, Kroon M, Hsiao N-y, Myer L. Field evaluation of HIV point-of-care testing for early infant diagnosis in Cape Town, South Africa. PloS one. 2017;12(12):e0189226 10.1371/journal.pone.0189226
    1. Hsiao N-y, Dunning L, Kroon M, Myer L. Laboratory evaluation of the Alere q point-of-care system for early infant HIV diagnosis. PloS one. 2016;11(3):e0152672 10.1371/journal.pone.0152672
    1. Ibrahim M, Moyo S, Mohammed T, Mupfumi L, Gaseitsiwe S, Maswabi K, et al. Brief Report: High Sensitivity and Specificity of the Cepheid Xpert HIV-1 Qualitative Point-of-Care Test Among Newborns in Botswana. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2017;75(5):e128–e31. 10.1097/QAI.0000000000001384
    1. Jani IV, Meggi B, Mabunda N, Vubil A, Sitoe NE, Tobaiwa O, et al. Accurate early infant HIV diagnosis in primary health clinics using a point-of-care nucleic acid test. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2014;67(1):e1–e4. 10.1097/QAI.0000000000000250
    1. Murray TY, Sherman GG, Nakwa F, MacLeod WB, Sipambo N, Velaphi S, et al. Field Evaluation of Performance of Alere and Cepheid Qualitative HIV Assays for Pediatric Point-of-Care Testing in an Academic Hospital in Soweto, South Africa. Journal of clinical microbiology. 2017;55(11):3227–35. 10.1128/JCM.01021-17
    1. Ondiek J, Namukaya Z, Mtapuri-Zinyowera S, Balkan S, Elbireer A, Lumb IU, et al. Multicountry Validation of SAMBA-A Novel Molecular Point-of-Care Test for HIV-1 Detection in Resource-Limited Setting. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2017;76(2):e52–e7. 10.1097/QAI.0000000000001476
    1. Michaeli M, Wax M, Gozlan Y, Rakovsky A, Mendelson E, Mor O. Evaluation of xpert HIV-1 qual assay for resolution of HIV-1 infection in samples with negative or indeterminate geenius HIV-1/2 results. Journal of Clinical Virology. 2016;76:1–3. 10.1016/j.jcv.2015.12.009
    1. Rakovsky A, Gozlan Y, Bassal R, Wax M, Shirazi R, Bakhanashvili M, et al. Diagnosis of HIV-1 infection: Performance of Xpert Qual and Geenius supplemental assays in fourth generation ELISA-reactive samples. Journal of Clinical Virology. 2018;101:7–10. 10.1016/j.jcv.2018.01.007
    1. Garrett NJ, Drain P, Werner L, Samsunder N, Karim SSA. Diagnostic Accuracy of the Point-of-care Xpert® HIV-1 Viral Load Assay in a South African HIV clinic. Journal of acquired immune deficiency syndromes (1999). 2016;72(2):e45.
    1. Avidor B, Matus N, Girshengorn S, Achsanov S, Gielman S, Zeldis I, et al. Comparison between Roche and Xpert in HIV-1 RNA quantitation: A high concordance between the two techniques except for a CRF02_AG subtype variant with high viral load titters detected by Roche but undetected by Xpert. Journal of Clinical Virology. 2017;93:15–9. 10.1016/j.jcv.2017.05.014
    1. Bruzzone B, Caligiuri P, Nigro N, Arcuri C, Delucis S, Di Biagio A, et al. Xpert HIV-1 Viral Load Assay and VERSANT HIV-1 RNA 1.5 Assay: A Performance Comparison. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2017;74(3):e86–e8. 10.1097/QAI.0000000000001227
    1. Goel N, Ritchie AV, Mtapuri-Zinyowera S, Zeh C, Stepchenkova T, Lehga J, et al. Performance of the SAMBA I and II HIV-1 Semi-Q Tests for viral load monitoring at the point-of-care. Journal of virological methods. 2017;244:39–45. 10.1016/j.jviromet.2017.03.001
    1. Gous N, Scott L, Berrie L, Stevens W. Options to expand HIV viral load testing in South Africa: evaluation of the GeneXpert® HIV-1 viral load assay. PloS one. 2016;11(12):e0168244 10.1371/journal.pone.0168244
    1. Gueudin M, Baron A, Alessandri-Gradt E, Lemée V, Mourez T, Etienne M, et al. Performance evaluation of the new HIV-1 quantification assay, Xpert HIV-1 viral load, on a wide panel of HIV-1 variants. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2016;72(5):521–6. 10.1097/QAI.0000000000001003
    1. Hopkins M, Hau S, Tiernan C, Papadimitropoulos A, Chawla A, Beloukas A, et al. Comparative performance of the new Aptima HIV-1 Quant Dx assay with three commercial PCR-based HIV-1 RNA quantitation assays. Journal of Clinical Virology. 2015;69:56–62. 10.1016/j.jcv.2015.05.020
    1. Jani IV, Meggi B, Vubil A, Sitoe NE, Bhatt N, Tobaiwa O, et al. Evaluation of the whole-blood Alere Q NAT point-of-care RNA assay for HIV-1 viral load monitoring in a primary health care setting in Mozambique. Journal of clinical microbiology. 2016;54(8):2104–8. 10.1128/JCM.00362-16
    1. Jordan JA, Plantier J, Templeton K, Wu A. Multi-site clinical evaluation of the Xpert® HIV-1 viral load assay. Journal of Clinical Virology. 2016;80:27–32. 10.1016/j.jcv.2016.04.014
    1. Kulkarni S, Jadhav S, Khopkar P, Sane S, Chimanpure V, Dhilpe V, et al., editors. GeneXpert HIV-1 Quant: a tool for monitoring the success of ART programme in developing countries. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY; 2016: INT AIDS SOCIETY AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND.
    1. Mor O, Gozlan Y, Wax M, Mileguir F, Rakovsky A, Noy B, et al. Evaluation of the RealTime HIV-1, Xpert HIV-1, and Aptima HIV-1 quant Dx assays in comparison to the NucliSens EasyQ HIV-1 v2. 0 assay for quantification of HIV-1 viral load. Journal of clinical microbiology. 2015;53(11):3458–65. 10.1128/JCM.01806-15
    1. Moyo S, Mohammed T, Wirth KE, Prague M, Bennett K, Holme MP, et al. Point-of-care Cepheid Xpert HIV-1 viral load test in rural African communities is feasible and reliable. Journal of clinical microbiology. 2016;54(12):3050–5. 10.1128/JCM.01594-16
    1. Nash M, Ramapuram J, Kaiya R, Huddart S, Pai M, Baliga S. Use of the GeneXpert tuberculosis system for HIV viral load testing in India. The Lancet Global Health. 2017;5(8):e754–e5. 10.1016/S2214-109X(17)30247-4
    1. Ritchie AV, Ushiro-Lumb I, Edemaga D, Joshi HA, De Ruiter A, Szumilin E, et al. SAMBA HIV semiquantitative test, a new point-of-care viral-load-monitoring assay for resource-limited settings. Journal of clinical microbiology. 2014;52(9):3377–83. 10.1128/JCM.00593-14
    1. Schalasta G, Börner A, Speicher A, Enders M. Comparative evaluation of the Aptima HIV-1 Quant Dx assay and COBAS TaqMan HIV-1 v2. 0 assay using the Roche High Pure System for the quantification of HIV-1 RNA in plasma. Clinical Chemistry and Laboratory Medicine (CCLM). 2016;54(3):493–9. 10.1515/cclm-2015-0522
    1. Schønning K, Johansen K, Landt B, Benfield T, Westh H. Comparison of the Hologic Aptima HIV-1 Quant Dx Assay to the Roche COBAS Ampliprep/COBAS TaqMan HIV-1 Test v2. 0 for the quantification of HIV-1 RNA in plasma samples. Journal of Clinical Virology. 2017;92:14–9. 10.1016/j.jcv.2017.05.006
    1. Swathirajan CR, Vignesh R, Boobalan J, Solomon SS, Saravanan S, Balakrishnan P. Performance of point-of-care Xpert HIV-1 plasma viral load assay at a tertiary HIV care centre in Southern India. Journal of medical microbiology. 2017;66(10):1379–82. 10.1099/jmm.0.000514
    1. Titchmarsh L, Zeh C, Verpoort T, Allain J-P, Lee H. Leukodepletion as a point-of-care method for monitoring HIV-1 viral load in whole blood. Journal of clinical microbiology. 2015;53(4):1080–6. 10.1128/JCM.02853-14
    1. Saag MS, Holodniy M, Kuritzkes D, O'Brien W, Coombs R, Poscher M, et al. HIV viral load markers in clinical practice. Nature medicine. 1996;2(6):625–9.
    1. Sollis KA, Smit PW, Fiscus S, Ford N, Vitoria M, Essajee S, et al. Systematic Review of the Performance of HIV Viral Load Technologies on Plasma Samples. PLOS ONE. 2014;9(2):e85869 10.1371/journal.pone.0085869
    1. WHO. WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: Xpert® HIV-1 Viral Load 2017 [cited 2018 17 April ]. Available from: .
    1. WHO. CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION 2016 [cited 2018 16 April]. Second:[Available from: .
    1. Essajee S, Bhairavabhotla R, Penazzato M, Kiragu K, Jani I, Carmona S, et al. Scale-up of Early Infant HIV Diagnosis and Improving Access to Pediatric HIV Care in Global Plan Countries: Past and Future Perspectives. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2017;75:S51–S8. 10.1097/QAI.0000000000001319 00126334-201705011-00008.
    1. Marston M, Becquet R, Zaba B, Moulton LH, Gray G, Coovadia H, et al. Net survival of perinatally and postnatally HIV-infected children: a pooled analysis of individual data from sub-Saharan Africa. International Journal of Epidemiology. 2011;40(2):385–96. 10.1093/ije/dyq255
    1. Innes S, Lazarus E, Otwombe K, Liberty A, Germanus R, Van Rensburg AJ, et al. Early severe HIV disease precedes early antiretroviral therapy in infants: Are we too late? Journal of the International AIDS Society. 2014;17(1).
    1. Karidia D, Surbhi M, Mackenzie H, Suzanne BR, NJ N. A Proposed Framework for the Implementation of Early Infant Diagnosis Point-of-Care. AIDS Research and Human Retroviruses. 2017;33(3):203–10. 10.1089/AID.2016.0021 .
    1. WHO. PROGRESS REPORT 2016: PREVENT HIV, TEST AND TREAT ALL 2016 [cited 2018 10 April]. Available from: .
    1. WHO. Global Action Plan on HIV Drug Resistance 2017–2021: 2018 Progress Report: WHO; 2018 [updated July cited 2018 09 October ]. Available from: .
    1. WHO. Low-cost tools for diagnosing and monitoring HIV infection in low-resource settings 2012 [cited 2018 14 April]. Available from: .
    1. Peter T, Zeh C, Katz Z, Elbireer A, Alemayehu B, Vojnov L, et al. Scaling up HIV viral load–lessons from the large-scale implementation of HIV early infant diagnosis and CD4 testing. Journal of the International AIDS Society. 2017;20(S7):e25008 10.1002/jia2.25008
    1. Roberts T, Cohn J, Bonner K, Hargreaves S. Scale-up of Routine Viral Load Testing in Resource-Poor Settings: Current and Future Implementation Challenges. Clinical Infectious Diseases. 2016;62(8):1043–8. 10.1093/cid/ciw001
    1. MSF. Making Viral Load Routine 2016 [cited 2018 09 October ]. Available from: .
    1. Powers KA, Cohen MS. Acute HIV-1 infection in sub-Saharan Africa: a common occurrence overlooked. AIDS. 2014;28(9):1365–7. 10.1097/QAD.0000000000000277 00002030-201406010-00015.
    1. Rutstein SE, Ananworanich J, Fidler S, Johnson C, Sanders EJ, Sued O, et al. Clinical and public health implications of acute and early HIV detection and treatment: a scoping review. Journal of the International AIDS Society. 2017;20(1):21579 10.7448/IAS.20.1.21579 PMC5515019.
    1. Sanders EJ, Wahome E, Powers KA, Werner L, Fegan G, Lavreys L, et al. Targeted screening of at-risk adults for acute HIV-1 infection in sub-Saharan Africa. AIDS (London, England). 2015;29(0 3):S221.
    1. Fund TG. HIV Viral Load and Early Infant Diagnosis Selection and Procurement Information Tool 2017 [updated April 2017; cited 2018 18 October ]. Available from: .
    1. Stevens W, Gous N, Ford N, Scott LE. Feasibility of HIV point-of-care tests for resource-limited settings: challenges and solutions. BMC Medicine. 2014;12(1):173 10.1186/s12916-014-0173-7

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren